Theriva Biologics (TOVX) posted a first quarter net loss to stockholders of $4.3 million compared to a loss of $5.2 million, prior year. Net loss per share was $1.55 compared to a loss of $7.53. Cash and cash equivalents were $10 million as of March 31, 2025, compared to $11.6 million as of December 31, 2024.
Steven Shallcross, CEO of Theriva Biologics, said: "The VIRAGE Phase 2b clinical trial of VCN-01 with gemcitabine/nab-paclitaxel in newly diagnosed metastatic pancreatic cancer patients achieved its primary survival and safety endpoints. We are working to scale up manufacturing and finalize the design of a Phase 3 trial of VCN-01 with gemcitabine/nab-paclitaxel."
For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
April 10, 2026 16:21 ET Inflation data from the U.S. was the main data event this week as the conflict in the Middle East continue. The minutes of the latest Fed policy session and the survey data on the services sector also made headlines. In Europe, manufacturing orders data from Germany was in focus. Price data from China drew attention in Asia.